摘要
[目的]比较HP及MVP方案对晚期非小细胞肺癌的疗效和毒性。[方法]分析HP及MVP化疗方案治疗59例晚期非小细胞肺癌。[结果]HP组有效率为50.0%(其中5例复治者中PR3例),MVP组有效率为51.6%,两组间无差异性(P>0.05),毒性反应以骨髓抑制、恶心呕吐及腹泻为主。[结论]HP方案是治疗晚期非小细胞肺癌的有效方案。
To compare the efficacy and toxicity of HP regimen(HCPT and DDP)and MVP regimen(MMC,VDS and DDP)in advanced non-small cell lung cancer(NSCLC).The clinical data of59cases with advanced NSCLC treated with HP and MVP were analysed.The response rate was50%in patients with HP group(there were3PR in5previousely treated cases),51.6%in patients with MVP group.There was no significant difference between two groups(P>0.05).The major toxicities in the two groups were leucopenia,nausea and diarrhea.[Conclusion]HP regimen is effective for the treatment of advanced NSCLC patients.
出处
《肿瘤学杂志》
CAS
2004年第1期23-24,共2页
Journal of Chinese Oncology
关键词
癌
非小细胞肺
药物疗法
羟基喜树碱
拓扑异构酶
顺铂
cancer,non-small cell lung
drug therapy
hydrosylcamptothecin
topoisomerase
cisplatin
